Last reviewed · How we verify
NCT04673279
Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina
trial testing serology in Coronavirus Disease 2019 in 189 participants. Completed in 20 August 2021.
20 August 2021
Quick facts
| Lead sponsor | Hospital Italiano de Buenos Aires |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 189 |
| Start date | 2 December 2020 |
| Primary completion | 20 August 2021 |
| Estimated completion | 20 August 2021 |
| Sites | 1 location across Argentina |
Drugs / interventions tested
- serology — full drug profile →
Conditions studied
- Coronavirus Disease 2019 — all drugs for Coronavirus Disease 2019 →
Sponsor
Hospital Italiano de Buenos Aires
Who can join
Adults 14 to 90, any sex, with Coronavirus Disease 2019. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Between June 10t h and July 1st, a cross-sectional design study in an Argentina slum, showed a prevalence based on immunoglobuling G-class (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) of 53.4%. It remains unanswered whether natural infection produces sustained antibodies. The aim of this study is to evaluate the presence of IgG antibodies for Coronavirus disease 2019 (COVID-19) after 5 months in inhabitants of Barrio 31 who consented the Seroprevalence Study for COVID-19.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Long-Term Duration of Antibody Response to SARS CoV-2 in One of the Largest Slums of Buenos Aires
Pagotto V, Luna L, Salto J, Manslau MW, et al · · 2021 · DOI 10.1101/2021.03.05.21253010
Verify or expand the search:
- PubMed search for NCT04673279
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of serology
Trials testing the same drug.
- NCT05128656 — Immune Response of Asymptomatic EHPAD Employees Infected With COVID-19 · NA · withdrawn
- NCT04935528 — Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried · NA · completed
- NCT04553575 — CoViD-19 Patient in Reims University Hospital in March to April 2020 · completed
- NCT04543006 — Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 · NA · unknown
Other recruiting trials for Coronavirus Disease 2019
Currently open trials in the same condition.
- NCT05160636 — A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza · active not recruiting
- NCT05164744 — Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors · recruiting
Other Hospital Italiano de Buenos Aires trials
Trials by the same sponsor.
- NCT07397416 — Impact of Implementing a Rapid PCR-based Algorithm for Carbapenemase-producing Enterobacterales (CPE) and Infection Cont · NA · not yet recruiting
- NCT07167173 — Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis · not yet recruiting
- NCT06683781 — Ventilatory Settings and Monitoring Variables Associated With Weaning Failure in Critically Ill Patients · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT06609798 — Ultrasound Assessment During Weaning from Mechanical Ventilation · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04673279 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Italiano de Buenos Aires
- Last refreshed: 25 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04673279.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing